Celina M. Scally Sells 1,278 Shares of Apria, Inc. (NYSE:APR) Stock

Apria, Inc. (NYSE:APR) SVP Celina M. Scally sold 1,278 shares of the stock in a transaction dated Wednesday, October 13th. The stock was sold at an average price of $32.35, for a total transaction of $41,343.30. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

NYSE:APR opened at $32.41 on Thursday. The company has a current ratio of 1.21, a quick ratio of 1.18 and a debt-to-equity ratio of 215.95. Apria, Inc. has a 52 week low of $20.07 and a 52 week high of $40.00. The firm has a 50-day moving average price of $35.52 and a two-hundred day moving average price of $31.21.

Apria (NYSE:APR) last posted its quarterly earnings data on Thursday, August 5th. The company reported $0.54 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.37 by $0.17. The firm had revenue of $286.28 million during the quarter, compared to analysts’ expectations of $280.18 million. Equities analysts forecast that Apria, Inc. will post 1.63 earnings per share for the current year.

A number of large investors have recently bought and sold shares of APR. American International Group Inc. purchased a new stake in Apria in the 1st quarter valued at about $123,000. BlackRock Inc. purchased a new stake in Apria in the 1st quarter valued at about $10,898,000. New York State Common Retirement Fund purchased a new stake in Apria in the 1st quarter valued at about $95,000. UBS Group AG purchased a new stake in shares of Apria during the 1st quarter worth approximately $78,000. Finally, JPMorgan Chase & Co. purchased a new stake in shares of Apria during the 1st quarter worth approximately $79,000. Hedge funds and other institutional investors own 94.99% of the company’s stock.

A number of equities analysts have recently issued reports on APR shares. Piper Sandler increased their price objective on shares of Apria from $33.00 to $35.00 and gave the stock an “overweight” rating in a research report on Friday, August 6th. initiated coverage on shares of Apria in a research report on Wednesday, June 30th. They issued a “buy” rating and a $33.00 price target on the stock. The Goldman Sachs Group cut shares of Apria from a “buy” rating to a “neutral” rating and dropped their price target for the company from $32.00 to $29.00 in a research report on Monday, July 19th. Zacks Investment Research cut shares of Apria from a “buy” rating to a “hold” rating in a research report on Wednesday, October 6th. Finally, Citigroup raised their price target on shares of Apria from $33.00 to $38.00 and gave the company a “buy” rating in a research report on Friday, August 6th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $31.86.

About Apria

Apria, Inc provides integrated home healthcare equipment and related services in the United States. The company offers home respiratory therapies, including the supply of stationary and portable home oxygen equipment, and non-invasive ventilators; obstructive sleep apnea therapy devices comprising continuous positive airway pressure and bi-level positive airway pressure devices, and patient support services; and negative pressure wound therapy products.

Further Reading: What is the QQQ ETF?

Insider Buying and Selling by Quarter for Apria (NYSE:APR)

Receive News & Ratings for Apria Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apria and related companies with MarketBeat.com's FREE daily email newsletter.